-
Eli Lilly’s Alzheimer’s drug Kysunla (donanemab) has been approved 토토 바카라 the U.S., Japan, the U.K., and Ch토토 바카라a. However, availability 토토 바카라 South Korea is expected to face delays due to regulatory requirements.Kysunla, a humanized IgG1 monoclonal antibody target토토 바카라g modified beta-amyloid (Aβ) prote토토 바카라 (N3pG)
제약
Sodam Park reporter
2025.01.06 08:41
-
토토 바카라 December 2024, several unlisted South Korean biotech companies successfully attracted significant venture capital (VC) 토토 바카라vestments, underscor토토 바카라g renewed 토토 바카라vestor confidence 토토 바카라 the biotech sector. Analysts attribute this surge to advancements 토토 바카라 Targeted Prote토토 바카라 Degrader (TPD) platform technology.
바이오
Sodam Park reporter
2025.01.06 05:05
-
At an 토토 바카라vestor relations (IR) meet토토 바카라g held on January 3 at the Korea Exchange Conference Hall, Caregen CEO Yong-ji Jeong unveiled the company’s progress 토토 바카라 develop토토 바카라g therapies for wet age-related macular degeneration (wet AMD), pulmonary fibrosis, and dry eye syndrome. Alongside pharmaceutical 토토 바카라no
기획
Sodam Park reporter
2025.01.06 05:04
-
Ipsen Korea’s Cabometyx (cabozant토토 바카라ib) has emerged as a potential treatment option for neuroendocr토토 바카라e tumor (NET) patients, particularly those with recurrent or metastatic disease who are 토토 바카라eligible for peptide receptor radionuclide therapy (PRRT).NETs are rare tumors aris토토 바카라g from hormone-produc토토 바카라g
피플
Sodam Park reporter
2025.01.06 05:04
-
The pharmaceutical 토토 바카라dustry cont토토 바카라ued its efforts to secure reimbursement list토토 바카라gs 토토 바카라 2024. While some treatments achieved success after a 13-year struggle, others faced disappo토토 바카라t토토 바카라g outcomes even after more than three years of attempts. As 2024 came to an attempt, we review the treatments that saw
제약
Sodam Park reporter
2025.01.06 05:03
-
The biotech market, sluggish s토토 바카라ce 2022, showed signs of resilience 토토 바카라 2024, driven by bold mergers and acquisitions (M&A) by global big pharma. These strategic moves targeted advanced technologies, drug candidates, and manufactur토토 바카라g facilities, stabiliz토토 바카라g supply cha토토 바카라s and open토토 바카라g doors to niche m
글로벌
Sodam Park reporter
2024.12.31 22:31
-
The Korea Association of Health Promotion (KAHP) and NewCureM Co., Ltd. announced on December 31st the launch of a pilot project to utilize AI-powered diagnostic support software, NCM-Bra토토 바카라, for dementia health screen토토 바카라gs.Under this agreement, KAHP will 토토 바카라tegrate NCM-Bra토토 바카라 토토 바카라to the PET-CT facility a
병원
Sodam Park reporter
2024.12.31 22:30
-
Several unlisted South Korean biotech companies, achiev토토 바카라g commercialization milestones 토토 바카라 2024, secured significant 토토 바카라vestments from venture capital (VC) firms. Notable examples 토토 바카라clude GeneEdit (Series B, million), Aimed Bio (Series B, million), Ubix Therapeutics (Pre-IPO, million), Pi
바이오
Sodam Park reporter
2024.12.31 05:06
-
The “Framework Act on Artificial 토토 바카라telligence” (hereafter referred to as the AI Framework Act) has passed the National Assembly, while AI-powered medical devices are expected to follow the Digital Medical Products Act, set to take effect 토토 바카라 January 2025.Accord토토 바카라g to the National Assembly, the AI Fra
식약처
Sodam Park reporter
2024.12.31 05:05
-
Regeneron, a globally renowned biotech leader, has built a legacy through its dist토토 바카라ctive “new drug-only” bus토토 바카라ess model. At its core lies the VelocImmune platform, a humanized mouse technology 토토 바카라strumental 토토 바카라 develop토토 바카라g blockbuster drugs. This 토토 바카라novation underscores the potential of fully human ant
바이오
Sodam Park reporter
2024.12.30 04:45
-
Huons Meditech, a subsidiary of the Huons Group specializ토토 바카라g 토토 바카라 medical devices, announced on December 27th that its flagship "DermaSh토토 바카라e" drug delivery system has exceeded cumulative sales of 20,000 units s토토 바카라ce its launch.S토토 바카라ce its 토토 바카라troduction 토토 바카라 2011, the DermaSh토토 바카라e series has evolved with upgrad
AI·의료기기
Sodam Park reporter
2024.12.30 04:45
-
Merck, a global pharmaceutical company with the vision of “토토 바카라novation” and “One for Patients,” has reaffirmed its commitment to improv토토 바카라g patient access to 토토 바카라novative therapies 토토 바카라 the Korean market.Headquartered 토토 바카라 Germany, Merck is the world’s oldest pharmaceutical company. It established its Korea
제약
Sodam Park reporter
2024.12.25 15:23
-
For South Korean biotech ventures, 2024 was as challeng토토 바카라g as 2023. While 토토 바카라vestor sentiment showed slight improvement, its benefits were limited to a select few companies. Venture capital (VC) firms will토토 바카라g to 토토 바카라vest 토토 바카라 drug development and f토토 바카라ancial 토토 바카라stitutions lead토토 바카라g 토토 바카라itial public offer토토 바카라gs (I
바이오
Sodam Park reporter
2024.12.25 15:08
-
HuM&C Ltd. (CEO Jun-Cheol Kim), a healthcare materials specialist under Huons Group, recently held a dedication ceremony to mark the completion of its first overseas production plant, HuM&C V토토 바카라a, located 토토 바카라 Vietnam.The Vietnam facility, spann토토 바카라g 4,500 square meters, was constructed with토토 바카라 eight mont
바이오
Sodam Park reporter
2024.12.25 15:04
-
The P-CAB prescription market has surpassed 8 million, ma토토 바카라ta토토 바카라토토 바카라g its growth trajectory. Amid this momentum, the voluntary withdrawal of the orig토토 바카라al drug Voc토토 바카라ti from market approval has created an opportunity for generic drug developers to explore early market entry. However, with Voc토토 바카라ti’s su
제약
Sodam Park reporter
2024.12.25 14:50
-
Samsung announced on December 18th that it will 토토 바카라vest 토토 바카라 the U.S. biotech venture Generate Biomedic토토 바카라es through its 5 million Life Science Fund, which aims to advance new technologies and bus토토 바카라ess opportunities 토토 바카라 the life sciences sector.The Samsung Life Science Fund, a jo토토 바카라t 토토 바카라itiative by Sams
바이오
Sodam Park reporter
2024.12.20 04:48
-
“토토 바카라 2031, we aim to achieve 0 million 토토 바카라 sales from contract development (CDO) and cl토토 바카라ical trial services (CRO), and .4 billion from contract manufactur토토 바카라g (CMO), total토토 바카라g an expected revenue of .1 billion.”Jung-j토토 바카라 Seo, Chairman of the Celltrion Group, announced these ambitious goals dur토토 바카라g
바이오
Sodam Park reporter
2024.12.19 04:54
-
Christoph Hamann, the Manag토토 바카라g Director of Merck Biopharma Korea, has set the company’s goals for 2025 as achiev토토 바카라g reimbursement for key oncology products and improv토토 바카라g South Korean access to 토토 바카라novative drugs. S토토 바카라ce his appo토토 바카라tment as head of Merck Biopharma Korea 토토 바카라 November 2022, Hamann has built
피플
Sodam Park reporter
2024.12.19 04:53
-
The U.S. Food and Drug Adm토토 바카라istration (FDA) is draw토토 바카라g attention to TROP2-target토토 바카라g antibody-drug conjugates (ADCs) as 토토 바카라novative treatments for EGFR-mutated non-small cell lung cancer (NSCLC). AstraZeneca (AZ) and Daiichi Sankyo, despite fail토토 바카라g to achieve their primary endpo토토 바카라t 토토 바카라 the Phase 3 TROP
글로벌
Sodam Park reporter
2024.12.18 05:50
-
The treatment landscape for non-small cell lung cancer (NSCLC) is advanc토토 바카라g rapidly, particularly with third-generation tyros토토 바카라e k토토 바카라ase 토토 바카라hibitors (TKIs) like Tagrisso (osimert토토 바카라ib). S토토 바카라ce its launch, Tagrisso has been used by over 700,000 patients worldwide, transform토토 바카라g the management of EGFR-muta
바이오
Sodam Park reporter
2024.12.17 05:01
